Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer Patients With Detectable PSA Following Prostatectomy”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Early research (Phase 1)Study completedNCT01548807
What this trial is testing

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Who this might be right for
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Abramson Cancer Center at Penn Medicine 19
Large-scale testing (Phase 3)Looking for participantsNCT06970847
What this trial is testing

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

Who this might be right for
Prostate CancerProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer Recurrent+3 more
Clarity Pharmaceuticals Ltd 220